Glancy Prongay & Murray LLP (“GPM”) commences its investigation on behalf of INC Research Holdings, Inc. (“INCR” or the “Company”) (NASDAQ: INCR) investors concerning the Company and its officers’ possible violations of federal securities law. To obtain information or aid in the investigation, please visit the INCR page on our website at www.glancylaw.com.
On November 9, 2017, INC Research reported its first financial results after combining with inVentiv Health. The Company’s combined results were negatively impacted by merger-related expenses, an impairment charge and increased amortization expenses. The price of INC Research stock fell significantly following the announcement.
On this news, INCR’s stock price fell nearly 30%, or $16.35 per share, to close at $41.15 per share on November 9, 2017, thereby injuring investors.
If you purchased INCR securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley F. Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171109006798/en/
Glancy Prongay & Murray LLP, Los Angeles/New York
Lesley F.
Portnoy, 310-201-9150 or 888-773-9224
[email protected]
www.glancylaw.com